Italia Markets open in 5 hrs 45 mins

Orion Oyj (0M2O.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
45,91-0,46 (-0,99%)
Alla chiusura: 04:57PM GMT

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Settore/i
Settore
Impiegati a tempo pieno3.632

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Liisa HurmePresident, CEO & Chairman of Executive Management Board770,28kN/D1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO & Member of the Executive Management BoardN/DN/D1961
Mr. Olli Huotari Ll.M.Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management BoardN/DN/D1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. BoardN/DN/D1966
Ms. Virve Laitinen M.Sc. (Tech.), MBASr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. BoardN/DN/D1972
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/DN/D1962
Mr. Juhani KankaanpaaSenior VP of Global Operations & Member of Executive Management BoardN/DN/DN/D
Mr. Niclas Lindstedt EMBA, M.Sc.Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. BoardN/DN/DN/D
Mr. Hao Pan M.Sc.Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. BoardN/DN/D1971
Ms. Julia Irene MachareySenior Vice President of People & Culture and Member of Management BoardN/DN/D1977
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Additionally, the company has research collaboration and licensing agreement with Glykos Finland Oy to develop next-generation antibody-drug conjugates. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Governance aziendale

L'ISS Governance QualityScore di Orion Oyj al 1 marzo 2024 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 1; diritti degli azionisti: 10; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.